Hengrui Medicine (01276): HRS-6208 Capsules, HRS-6209 Capsules, HRS-8080 Tablets, HRS-1358 Tablets, HRS-5041 Tablets have been approved to conduct clinical trials.

Zhijia Finance APP News, Hengrui Medicine (01276) announced that recently, the company and its subsidiaries Shanghai Hengrui Medicine Co., Ltd., Shandong Shengdi Medicine Co., Ltd., and Chengdu Shengdi Medicine Co., Ltd. have received the Drug Clinical Trial Approval Notification for HRS-6208 Capsules, HRS-6209 Capsules, HRS-8080 Tablets, HRS-1358 Tablets, and HRS-5041 Tablets issued by the National Medical Products Administration, and will soon commence clinical trials.